{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:25:11Z","timestamp":1790634311806,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770213"],"award-info":[{"award-number":["81770213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["19JCYBJC26500"],"award-info":[{"award-number":["19JCYBJC26500"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-Roche20192-0097"],"award-info":[{"award-number":["Y-Roche20192-0097"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-XD2019-162"],"award-info":[{"award-number":["Y-XD2019-162"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clim.2023.109637","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T16:54:30Z","timestamp":1683305670000},"page":"109637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"251","author":[{"given":"Yaxiao","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengfeng","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingpei","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2023.109637_bb0005","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.clim.2023.109637_bb0010","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.clim.2023.109637_bb0015","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2023.109637_bb0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2023.109637_bb0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-07-741025","article-title":"The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy","volume":"131","author":"Buchan","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.clim.2023.109637_bb0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba7308","article-title":"A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2023.109637_bb0035","doi-asserted-by":"crossref","first-page":"w98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.clim.2023.109637_bb0040","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/ng1532","article-title":"Reverse engineering of regulatory networks in human B cells","volume":"37","author":"Basso","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.clim.2023.109637_bb0045","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature."},{"key":"10.1016\/j.clim.2023.109637_bb0050","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt\u2019s lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2023.109637_bb0055","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2023.109637_bb0060","doi-asserted-by":"crossref","first-page":"1902880","DOI":"10.1002\/advs.201902880","article-title":"ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy","volume":"7","author":"Miao","year":"2020","journal-title":"Adv. Sci. (Weinh)."},{"key":"10.1016\/j.clim.2023.109637_bb0065","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.clim.2023.109637_bb0070","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clim.2023.109637_bb0075","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/ijc.32144","article-title":"Tumor CD73\/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome","volume":"145","author":"Wang","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.clim.2023.109637_bb0080","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1182\/blood.2019004725","article-title":"Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma","volume":"136","author":"Gaydosik","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.clim.2023.109637_bb0085","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","article-title":"Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells","volume":"167","author":"Boice","year":"2016","journal-title":"Cell."},{"key":"10.1016\/j.clim.2023.109637_bb0090","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2023.109637_bb0095","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1078-0432.CCR-1161-03","article-title":"T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma","volume":"10","author":"Lad\u00e1nyi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2023.109637_bb0100","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0002-9610(02)00831-0","article-title":"Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134)","volume":"183","author":"Petty","year":"2002","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.clim.2023.109637_bb0105","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1158\/1078-0432.CCR-15-2614","article-title":"OX40+ regulatory T cells in cutaneous squamous cell carcinoma suppress effector T-cell responses and associate with metastatic potential","volume":"22","author":"Lai","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2023.109637_bb0110","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1404214","article-title":"OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis","volume":"7","author":"Xie","year":"2018","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.clim.2023.109637_bb0115","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev."},{"key":"10.1016\/j.clim.2023.109637_bb0120","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1158\/1078-0432.CCR-19-1259","article-title":"Anti-OX40 antibody directly enhances the function of tumor-reactive CD8(+) T cells and synergizes with PI3K\u03b2 inhibition in PTEN loss melanoma","volume":"25","author":"Peng","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2023.109637_bb0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2023.109637_bb0130","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1182\/blood.V92.9.3338","article-title":"OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors","volume":"92","author":"Ohshima","year":"1998","journal-title":"Blood."},{"key":"10.1016\/j.clim.2023.109637_bb0135","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4049\/jimmunol.179.3.1427","article-title":"Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells","volume":"179","author":"So","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2023.109637_bb0140","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.celrep.2018.06.052","article-title":"OX40 costimulation inhibits Foxp3 expression and Treg induction via BATF3-dependent and independent mechanisms","volume":"24","author":"Zhang","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.clim.2023.109637_bb0145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ni743","article-title":"Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo","volume":"3","author":"Gavin","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2023.109637_bb0150","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.1900696","article-title":"OX40 agonist tumor immunotherapy does not impact regulatory T cell suppressive function","volume":"203","author":"Polesso","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2023.109637_bb0155","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/eji.200424863","article-title":"Functional expression of CD134 by neutrophils","volume":"34","author":"Baumann","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2023.109637_bb0160","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.4049\/jimmunol.173.6.3716","article-title":"Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions","volume":"173","author":"Zingoni","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2023.109637_bb0165","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/eji.200425721","article-title":"CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells","volume":"35","author":"Marschner","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2023.109637_bb0170","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1172\/JCI32693","article-title":"OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice","volume":"117","author":"Zaini","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2023.109637_bb0175","first-page":"1165","article-title":"Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice","volume":"118","author":"Liu","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2023.109637_bb0180","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.4049\/jimmunol.172.8.4821","article-title":"Costimulation of CD8 T cell responses by OX40","volume":"172","author":"Bansal-Pakala","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2023.109637_bb0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1615\/CritRevImmunol.v29.i3.10","article-title":"The role of OX40-mediated co-stimulation in T-cell activation and survival","volume":"29","author":"Redmond","year":"2009","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.clim.2023.109637_bb0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2023.109637_bb0195","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1073\/pnas.0712237105","article-title":"Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients","volume":"105","author":"Hodi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2023.109637_bb0200","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","article-title":"Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2023.109637_bb0205","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1038\/s41598-020-60738-4","article-title":"CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer","volume":"10","author":"Friese","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2023.109637_bb0210","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-019-0570-8","article-title":"The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation","volume":"7","author":"Kvarnhammar","year":"2019","journal-title":"J. Immunother Cancer."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623001365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623001365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:08:22Z","timestamp":1761494902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661623001365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":42,"alternative-id":["S1521661623001365"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2023.109637","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2023.109637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109637"}}